Clinical Trial Update: A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

View source ↗

Summary

A clinical trial studying end-of-dose phenomena in subcutaneous natalizumab-treated multiple sclerosis participants has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: TERMINATED